Apreo Health presents positive data on nitinol lung scaffold

Apreo Health today announced positive study results for its novel, self-expanding Breathe nitinol airway scaffold.

Menlo Park, California-based Apreo shared outcomes at the European Respiratory Society (ERS) Congress 2025 in Amsterdam. Findings demonstrated that Breathe improves lung function and quality of life, even in patients historically excluded from other interventions.

Apreo emerged from stealth to unveil its emphysema treatment in May. A week later, it shared promising first-in-human six-month clinical data supporting the use of the airway scaffold device. Last month, it closed an oversubscribed $130 million Series B financing round to support Breathe.

See full article (https://www.massdevice.com/apreo-positive-data-nitinol-lung-scaffold/)